Press Releases

Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023

February 8, 2023

Poseida Therapeutics Announces Board Change

January 31, 2023

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

December 11, 2022

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

December 6, 2022

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022

November 10, 2022

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

November 8, 2022

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress

November 3, 2022

Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition

November 3, 2022

Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting

October 5, 2022

Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022